Prognostic Impact of Combined Contrast-Induced Acute Kidney Injury and Hypoxic Liver Injury in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results from INTERSTELLAR Registry

Sang-Don Park, Jeonggeun Moon, Sung Woo Kwon, Young Ju Suh, Tae-Hoon Kim, Ho-Jun Jang, Jon Suh, Hyun Woo Park, Pyung Chun Oh, Sung-Hee Shin, Seong-Il Woo, Dae-Hyeok Kim, Jun Kwan, WoongChol Kang, Sang-Don Park, Jeonggeun Moon, Sung Woo Kwon, Young Ju Suh, Tae-Hoon Kim, Ho-Jun Jang, Jon Suh, Hyun Woo Park, Pyung Chun Oh, Sung-Hee Shin, Seong-Il Woo, Dae-Hyeok Kim, Jun Kwan, WoongChol Kang

Abstract

Background: Besides contrast-induced acute kidney injury(CI-AKI), adscititious vital organ damage such as hypoxic liver injury(HLI) may affect the survival in patients with ST-elevation myocardial infarction (STEMI). We sought to evaluate the prognostic impact of CI-AKI and HLI in STEMI patients who underwent primary percutaneous coronary intervention (PCI).

Methods: A total of 668 consecutive patients (77.2% male, mean age 61.3±13.3 years) from the INTERSTELLAR STEMI registry who underwent primary PCI were analyzed. CI-AKI was defined as an increase of ≥0.5 mg/dL in serum creatinine level or 25% relative increase, within 48h after the index procedure. HLI was defined as ≥2-fold increase in serum aspartate transaminase above the upper normal limit on admission. Patients were divided into four groups according to their CI-AKI and HLI states. Major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, non-fatal MI, non-fatal stroke, ischemia-driven target lesion revascularization and target vessel revascularization were recorded.

Results: Over a mean follow-up period of 2.2±1.6 years, 94 MACCEs occurred with an event rate of 14.1%. The rates of MACCE and all-cause mortality were 9.7% and 5.2%, respectively, in the no organ damage group; 21.3% and 21.3% in CI-AKI group; 18.5% and 14.6% in HLI group; and 57.7% and 50.0% in combined CI-AKI and HLI group. Survival probability plots of composite MACCE and all-cause mortality revealed that the combined CI-AKI and HLI group was associated with the worst prognosis (p<0.0001 for both).

Conclusion: Combined CI-AKI after index procedure and HLI on admission is associated with poor clinical outcomes in patients with STEMI who underwent primary PCI. (INTERSTELLAR ClinicalTrials.gov number, NCT02800421.).

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. 30-day mortality rates according to…
Fig 1. 30-day mortality rates according to CI-AKI and HLI states.
Abbreviations. CI-AKI = contrast induced acute kidney injury; HLI = hypoxic liver injury. ** p

Fig 2. Survival probability plots of MACCE…

Fig 2. Survival probability plots of MACCE and all cause mortality according to CI-AKI and…

Fig 2. Survival probability plots of MACCE and all cause mortality according to CI-AKI and HLI state after adjustment for age, diabetes mellitus, hypertension, MVD, Killip class, and LVEF using Kaplan-Meier method.
Abbreviations MACCE = major adverse cardiovascular and cerebrovascular event; CI-AKI = contrast induced acute kidney injury; HLI = hypoxic liver injury; MVD = multi-vessel disease; LVEF = left ventricular ejection fraction.
Fig 2. Survival probability plots of MACCE…
Fig 2. Survival probability plots of MACCE and all cause mortality according to CI-AKI and HLI state after adjustment for age, diabetes mellitus, hypertension, MVD, Killip class, and LVEF using Kaplan-Meier method.
Abbreviations MACCE = major adverse cardiovascular and cerebrovascular event; CI-AKI = contrast induced acute kidney injury; HLI = hypoxic liver injury; MVD = multi-vessel disease; LVEF = left ventricular ejection fraction.

References

    1. Roger VL, Weston SA, Gerber Y, Killian JM, Dunlay SM, Jaffe AS, et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction.Circulation 2010;121:863–9. 10.1161/CIRCULATIONAHA.109.897249
    1. Kostis WJ, Deng Y, Pantazopoulos JS, Moreyra AE, Kostis JB; Myocardial Infarction Data Acquisition System (MIDAS14) Study Group. Trends in mortality of acute myocardial infarction after discharge from the hospital.Circ Cardiovasc Qual Outcomes 2010;3:581–9. 10.1161/CIRCOUTCOMES.110.957803
    1. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes.JAMA 2007;298:765–75.
    1. Mamas MA, Anderson SG, O'Kane PD, Keavney B, Nolan J, Oldroyd KG, et al. Impact of left ventricular function in relation to procedural outcomes following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society.Eur Heart J 2014;35:3004–12a. 10.1093/eurheartj/ehu303
    1. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.Circulation 2009;119:1211–9. 10.1161/CIRCULATIONAHA.108.814947
    1. Giacoppo D, Madhavan MV, Baber U, Warren J, Bansilal S, Witzenbichler B, et al. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials.Circ Cardiovasc Interv 2015;8:e002475 10.1161/CIRCINTERVENTIONS.114.002475
    1. Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy.Eur Heart J 2014;35:1533–40. 10.1093/eurheartj/ehu063
    1. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al.Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry.JACC Cardiovasc Interv 2014;7:1–9. 10.1016/j.jcin.2013.06.016
    1. McCullough PA.Contrast-induced acute kidney injury.J Am Coll Cardiol 2008;51:1419–28. 10.1016/j.jacc.2007.12.035
    1. Moon J, Kang W, Oh PC, Seo SY, Lee K, Han SH, et al. Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary J Cardiol 2014;177:442–7. 10.1016/j.ijcard.2014.09.002
    1. Moon J, Suh J, Oh PC, Lee K, Park HW, Jang HJ, et al. Relation of Stature to Outcomes in Korean Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction (from the INTERSTELLAR Registry). Am J Cardiol 2016;118:177–82. 10.1016/j.amjcard.2016.04.046
    1. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501–55. 10.1093/eurheartj/ehq277
    1. Kwon SW, Kim JY, Suh YJ, Lee DH, Yoon YW, Lee BK, et al. Prognostic value of elevated homocysteine levels in Korean patients with coronary artery disease: a propensity score matched analysis. Korean Circ J 2016;46:154–60. 10.4070/kcj.2016.46.2.154
    1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–51.
    1. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–66. 10.1056/NEJMoa1409312
    1. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. 1993. Wiley-Interscience
    1. Andò G, de Gregorio C, Morabito G, Trio O, Saporito F, Oreto G. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014;7:465–72. 10.1161/CIRCINTERVENTIONS.114.001545
    1. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769–75.
    1. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780–5.
    1. Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol 2013;166:554–8. 10.1016/j.ijcard.2012.05.003
    1. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111–20.
    1. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, et al. Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 2011;37:1302–10. 10.1007/s00134-011-2248-7
    1. Ebert EC. Hypoxic liver injury. Mayo Clin Proc 2006;81:1232–6.
    1. Bynum TE, Boitnott JK, Maddrey WC. Ischemic hepatitis. Dig Dis Sci 1979;24:129–35.
    1. Cohen JA, Kaplan MM. Left-sided heart failure presenting as hepatitis. Gastroenterology 1978;74:583–7.
    1. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994;21:696–703.
    1. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457–64.

Source: PubMed

3
구독하다